Arrowhead Pharmaceuticals, Inc. ( NASDAQ: ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its fourth quarter and full year 2024 ...

Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt ...

Cendakimab fell short of the bar. The antibody hits IL-13, one of the interleukins targeted by Regeneron and Sanofi’s ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

Eric Benevich, the Chief Commercial Officer of Neurocrine Biosciences Inc (NASDAQ:NBIX), recently sold 1,207 shares of the company's common stock. The shares were sold at an average price of $152.94, ...

Given Sobi's cash flow generation from its hemophilia business and mature product Synagis, the firm ended 2024 with a net debt/EBITDA ratio of 1.6 times. We expect the firm can support this level of ...

Day One Bio aims to bring new cancer therapies to pediatric patients faster amid evolving financial incentives, such as the ...

Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue growth over the past decade.